LINA KAY: Open Payments
NPI 1275696288 · PHOENIX, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$295 in 15 payments from 10 companies in 2025. Trend: 2023 $1,210 · 2024 $1,243 · 2025 $295
Food & beverage: $295
| Company | Payments | Amount |
|---|---|---|
| Aimmune Therapeutics, Inc. | 2 | $61 |
| ABBVIE INC. | 3 | $50 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| PFIZER INC. | 2 | $37 |
| Novo Nordisk Inc | 1 | $22 |
| Merck Sharp & Dohme LLC | 1 | $19 |
| Exact Sciences Corporation | 1 | $19 |
| Novartis Pharmaceuticals Corporation | 1 | $18 |
| Ferring Pharmaceuticals Inc. | 1 | $17 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $16 |
Products named: ZENPEP, VRAYLAR, TRINTELLIX, NURTEC ODT, Wegovy, CAPVAXIVE, LEQVIO, ADSTILADRIN.
Industry payments across AZ — which companies pay providers there.
